ArticleBrain : a journal of neurology2023
Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study.
Article in Brain : a journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 72 citations in OpenAlex.
- Alzheimer Disease Blood Biomarkers and Cognition Among Individuals With Diabetes and Overweight or Obesity.JAMA network open · 2025Trial
- Brain pathology in relation to somatic diseases: Exploring the body-brain crosstalk.Journal of internal medicine · 2026Review
- Apolipoprotein E ε4 and type 2 diabetes cooperatively accelerate amyloid beta and tau neurodegeneration.European journal of nuclear medicine and molecular imaging · 2026Article
- Race and Ethnicity, Hypertension, and Neuroimaging Markers of Brain Aging: A Causal Mediation Analysis in the HABS-HD Study.Neurology · 2026Article
- Amyloid pathology and modifiable risk factors in cognitive decline among cognitively unimpaired older adults.The journal of prevention of Alzheimer's disease · 2026Article
- Epidemiological and clinical evidence on blood pressure management for the prevention of dementia: striving for a healthy 100-year life.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Diabetes and Hypertension at Midlife Predict Increases in Biomarkers of Dementia Among Black Americans.Journal of racial and ethnic health disparities · 2026Article
- Neutrophil inflammation metrics are associated with the risk of future dementia in large data from NYU Langone Hospitals and the Veterans Health Administration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Association of type 2 diabetes treatment status with in vivo biomarkers of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Sex Differences in Alzheimer Disease Imaging Biomarkers in a Diverse, Community-Based Cohort.JAMA network open · 2026Article
- Intracranial arterial calcification and cerebrovascular function in the general aging population - A 7T MRI Study.Cerebral circulation - cognition and behavior · 2026Article
- A unifying theory of brain signaling and its possible role in acquired chronic disease.Frontiers in neuroscience · 2026Article
- Hypertension as a Major Risk Factor in Alzheimer's Disease: Mechanisms, Interactions and Therapeutic Perspectives.Clinical interventions in aging · 2026Review
- Cerebral microbleed patterns and the risk of incident dementia in elderly adults: The ARIC study.PloS one · 2026Article
- Blood pressure and Alzheimer's disease biomarkers in cognitively unimpaired adults: a multicenter study.The journal of prevention of Alzheimer's disease · 2025Observational
- Human herpes viruses are associated with steeper age-dependent increases of serum biomarkers for dementia in cognitively unimpaired women.Scientific reports · 2025Article
- Differential effects of S-allyl cysteine and cannabidiol on enterocytic and plasma amyloid-β in db/db diabetic mice.Scientific reports · 2025Article
- Evaluation of plasma p-tau217 for detecting amyloid pathology in a heterogeneous community-based cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Non-Invasive Screening for Early Cognitive Impairment in Elderly Hyperuricaemic Men Using Transcranial Colour-Coded Duplex Sonography.Diagnostics (Basel, Switzerland) · 2025Article
- Multiorgan Imaging for Interorgan Crosstalk in Cardiometabolic Diseases.Circulation research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Higher vascular disease burden increases the likelihood of developing dementia, including Alzheimer's disease. Better understanding the association between vascular risk factors and Alzheimer's disease pathology at the predementia stage is critical for developing effective strategies to delay cognitive decline. In this work, we estimated the impact of six vascular risk factors on the presence and severity of in vivo measured brain amyloid-beta (Aβ) plaques in participants from the population-based Rotterdam Study. Vascular risk factors (hypertension, hypercholesterolaemia, diabetes, obesity, physical inactivity and smoking) were assessed 13 (2004-2008) and 7 years (2009-2014) prior to 18F-florbetaben PET (2018-2021) in 635 dementia-free participants. Vascular risk factors were associated with binary amyloid PET status or continuous PET readouts (standard uptake value ratios, SUVrs) using logistic and linear regression models, respectively, adjusted for age, sex, education, APOE4 risk allele count and time between vascular risk and PET assessment. Participants' mean age at time of amyloid PET was 69 years (range: 60-90), 325 (51.2%) were women and 190 (29.9%) carried at least one APOE4 risk allele. The adjusted prevalence estimates of an amyloid-positive PET status markedly increased with age [12.8% (95% CI 11.6; 14) in 60-69 years versus 35% (36; 40.8) in 80-89 years age groups] and APOE4 allele count [9.7% (8.8; 10.6) in non-carriers versus 38.4% (36; 40.8) to 60.4% (54; 66.8) in carriers of one or two risk allele(s)]. Diabetes 7 years prior to PET assessment was associated with a higher risk of a positive amyloid status [odds ratio (95% CI) = 3.68 (1.76; 7.61), P < 0.001] and higher standard uptake value ratios, indicating more severe Aβ pathology [standardized beta = 0.40 (0.17; 0.64), P = 0.001]. Hypertension was associated with higher SUVr values in APOE4 carriers (mean SUVr difference of 0.09), but not in non-carriers (mean SUVr difference 0.02; P = 0.005). In contrast, hypercholesterolaemia was related to lower SUVr values in APOE4 carriers (mean SUVr difference -0.06), but not in non-carriers (mean SUVr difference 0.02). Obesity, physical inactivity and smoking were not related to amyloid PET measures. The current findings suggest a contribution of diabetes, hypertension and hypercholesterolaemia to the pathophysiology of Alzheimer's disease in a general population of older non-demented adults. As these conditions respond well to lifestyle modification and drug treatment, further research should focus on the preventative effect of early risk management on the development of Alzheimer's disease neuropathology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.